Nuance Swallows Its Poison Pill

It's official, folks. Carl Icahn (or any investor for that matter) will not be able to acquire more than 20% of Nuance Communications' common shares outstanding without permission from the board of directors. As a result, Carl Icahn's activist investing spirit could be considerably crimped. Currently, Icahn owns approximately 16% of the voice-recognition company.

Additionally, there has been some speculation surrounding Icahn's recent stake in Apple and how he could be pushing for Apple to make a bid for Nuance.

In the following video, Fool contributor Steve Heller sits down with tech and telecom analysts Eric Bleeker and Jamal Carnette to discuss Nuance Communications' poison pill and any Apple-related rumors along the way.

The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!

The article Nuance Swallows Its Poison Pill originally appeared on Fool.com.

Eric Bleeker, CFA, has no position in any stocks mentioned. Jamal Carnette owns shares of Apple. Fool contributor Steve Heller owns shares of Apple and Nuance Communications. The Motley Fool recommends Apple and Nuance Communications. The Motley Fool owns shares of Apple and Nuance Communications. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.